Sports doping: Emerging designer and therapeutic B2-agonists

A.G. Fragkaki, C. Georgakopoulos, S.S. Sterk, M.W.F. Nielen

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)


Beta2-adrenergic agonists, or ß2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of ß2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel ß2-agonists molecules either by modifying the molecule of known ß2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging ß2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.
Original languageEnglish
Pages (from-to)242-258
Number of pages17
JournalClinica Chimica Acta
Publication statusPublished - 2013


  • acting beta(2)-adrenoreceptor agonists
  • chromatography-mass spectrometry
  • molecularly imprinted polymers
  • obstructive pulmonary-disease
  • beta-adrenergic agonists
  • performance liquid-chromatography
  • 2-dimensional gas-chromatography
  • developed bronchodilati

Fingerprint Dive into the research topics of 'Sports doping: Emerging designer and therapeutic B2-agonists'. Together they form a unique fingerprint.

Cite this